Formulated for ulcerative colitis and crohn's disease to manage intestinal inflammation and support mucosal healing.
Mechanism of Action
Pentasa releases mesalamine throughout the small and large intestine. It acts locally to inhibit cyclooxygenase and reduce the synthesis of inflammatory mediators like prostaglandins and leukotrienes.
Route of Administration
Oral
Onset Time
1–2 weeks
Duration
12–24 hours
Contraindications
Hypersensitivity to salicylates, Severe renal impairment, Severe hepatic impairment
Severe Adverse Events
Renal failure, Pancreatitis, Pericarditis — requires immediate medical attention
Information related to Pentasa is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
